当前位置:首页>产品中心>单抗/多抗>Anti-Human OTUD7B Polyclonal Antibody|抗人OTUD7B多克隆抗体(靶标:人OTU去泛素酶7B)

Anti-Human OTUD7B Polyclonal Antibody|抗人OTUD7B多克隆抗体(靶标:人OTU去泛素酶7B)

  • 货号:RB9THC193014
  • 价格:面议
  • 点击:1074
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human, Mouse
靶标Cellular zinc finger anti-NF-kappa-B protein, Cezanne, EC:3.4.19.12, OTU domain-containing protein 7B, OTUD7B, ZA20D1, Zinc finger A20 domain-containing protein 1, Zinc finger protein Cezanne
免疫原E. coli - derived recombinant Human OTUD7B (Gln136-Ser438).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q6GQQ9
背景信息

OTU domain-containing protein 7B (OTUD7B) is a ~92 kDa protein. Negative regulator of the non-canonical NF-kappa-B pathway that acts by mediating deubiquitination of TRAF3, an inhibitor of the NF-kappa-B pathway, thereby acting as a negative regulator of B-cell responses. In response to non-canonical NF-kappa-B stimuli, deubiquitinates 'Lys-48'-linked polyubiquitin chains of TRAF3, preventing TRAF3 proteolysis and over-activation of non-canonical NF-kappa-B. Negatively regulates mucosal immunity against infections. Deubiquitinates ZAP70, and thereby regulates T cell receptor (TCR) signaling that leads to the activation of NF-kappa-B. Plays a role in T cell homeostasis and is required for normal T cell responses, including production of IFNG and IL2.

1. Enesa, K. et al. (2008) The Journal of biological chemistry 283, 7036-45. PMID: 18178551
2. Hu, H. et al. (2016) The Journal of experimental medicine 213, 399-414. PMID: 26903241
3. Pareja, F. et al. (2012) Oncogene 31, 4599-608. PMID: 22179831
4. Evans, PC. et al. (2001) The Biochemical journal 357, 617-23. PMID: 11463333
5. Bremm, A. et al. (2010) Nature structural & molecular biology 17, 939-47. PMID: 20622874
6. Mevissen, TE. et al. (2013) Cell 154, 169-84. PMID: 23827681
7. Mevissen, TET. et al. (2016) Nature 538, 402-405. PMID: 27732584
8. Evans, PC. et al. (2003) The Journal of biological chemistry 278, 23180-6. PMID: 12682062
9. Wang, B. et al. (2017) Nature 545, 365-369. PMID: 28489822
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 1513
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 1221
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 1217
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 1418
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 1351
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 1388
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 1267
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 1283
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 1137
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 1486
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 1582
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 1498
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 1351
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 1147
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 1300
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 1500
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 1625
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 1592
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 1514
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 1509
总计 33037 个记录,共 1652 页,当前第 1651 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30